

**FIRST PROSPECTUS SUPPLEMENT DATED 31 JULY 2023  
TO THE BASE PROSPECTUS DATED 3 MAY 2023**



**DANONE**

€13,000,000,000

*Euro Medium Term Note Programme*

This first prospectus supplement (the "**First Prospectus Supplement**") constitutes a first prospectus supplement to and must be read in conjunction with the base prospectus dated 3 May 2023 prepared by Danone (the "**Issuer**" or "**Danone**") in relation to its €13,000,000,000 Euro Medium Term Note Programme (the "**Programme**") which received approval number 23-142 from the *Autorité des marchés financiers* (the "**AMF**") on 3 May 2023 (the "**Base Prospectus**"). Unless the context otherwise requires, terms defined in the Base Prospectus have the same meaning when used in this First Prospectus Supplement.

Application has been made for approval of this First Prospectus Supplement to the AMF in its capacity as competent authority under Regulation (EU) 2017/1129 of the European Parliament and of the European Council of 14 June 2017 (the "**Prospectus Regulation**").

This First Prospectus Supplement has been prepared pursuant to article 23 of the Prospectus Regulation, for the purposes of (i) incorporating by reference the Issuer's 2023 Interim Financial Report (ii) incorporating recent events in connection with the Issuer and (iii) as a consequence, amending and supplementing the "Risk Factors", "Documents Incorporated by Reference", "Recent Developments" and "General Information" sections of the Base Prospectus.

Save as disclosed in this First Prospectus Supplement, there has been no other significant new factor, material mistake or material inaccuracy relating to information included in the Base Prospectus which may affect the assessment of the Notes since the publication of the Base Prospectus.

To the extent there is any inconsistency between (a) any statement in this First Prospectus Supplement and (b) any other statement in or incorporated by reference in the Base Prospectus, the statements in (a) above will prevail.

Copies of this First Prospectus Supplement (a) may be obtained, free of charge, during normal business hours at the registered office of the Issuer, (b) will be available for viewing on the website of the Issuer ([www.danone.com](http://www.danone.com)), (c) will also be available on the website of the AMF (<https://www.amf-france.org>) and (d) will be available during usual business hours on any weekday (Saturdays, Sundays and public holidays excepted) for inspection at the offices of the Fiscal Agent and each of the Paying Agents.

## TABLE OF CONTENTS

RISK FACTORS	page 3
DOCUMENTS INCORPORATED BY REFERENCE	page 4
RECENT DEVELOPMENTS	page 12
GENERAL INFORMATION	page 24
PERSON RESPONSIBLE FOR THIS FIRST PROSPECTUS SUPPLEMENT	page 25

## **RISK FACTORS**

The paragraph below the heading "Risk Factors relating to the Issuer" on page 18 of the Base Prospectus is deleted and replaced as follows:

"Please refer to (i) pages 22 to 34 of the 2022 Universal Registration Document and (ii) page 11 of the 2023 Interim Financial Report (both as defined under "Documents incorporated by reference") which are incorporated by reference in this Base Prospectus and include the following:

- strategic risks;
- external environment risks; and
- operational risks."

## DOCUMENTS INCORPORATED BY REFERENCE

The section "Documents Incorporated by Reference" appearing on pages 32 to 38 of the Base Prospectus is deleted in its entirety and replaced by the following:

"This Base Prospectus should be read and construed in conjunction with the following:

- (a) the pages referred to in the table below included in the 2021 Universal Registration Document in the French language, filed with the AMF on 16 March 2022 under No. D. 22-0109, which contains the audited consolidated annual financial statements of Danone for the financial year ended 31 December 2021 (the **"2021 Universal Registration Document"**) (<https://www.danone.com/content/dam/danone-corp/danone-com/investors/fr-all-publications/2021/registrationdocuments/danoneurd2021fr.pdf>);
- (b) the pages referred to in the table below included in the 2022 Universal Registration Document in the French language, filed with the AMF on 16 March 2023 under No. D.23-0099, which contains the audited consolidated annual financial statements of Danone for the financial year ended 31 December 2022 (the **"2022 Universal Registration Document"**) (<https://www.danone.com/content/dam/danone-corp/danone-com/investors/fr-all-publications/2022/registrationdocuments/danoneurd2022fr.pdf>);
- (c) the pages referred to in the table below included in the 2023 Interim Financial Report in the French language for the six-month period ended 30 June 2023 which is dated 26 July 2023 (the **"2023 Interim Financial Report"**) (<https://www.danone.com/content/dam/corp/global/danonecom/investors/fr-all-publications/2023/interimfinancialreports/danone2023rapportsemestriel.pdf>); and
- (d) the terms and conditions of the notes contained in the base prospectuses of the Issuer dated 24 October 2014 ([https://www.danone.com/en/emtn-prospectus/2014/Prospectus\\_du\\_programme\\_EMTN\\_en\\_date\\_du\\_24\\_octobre\\_2014.pdf](https://www.danone.com/en/emtn-prospectus/2014/Prospectus_du_programme_EMTN_en_date_du_24_octobre_2014.pdf)), the **"2014 EMTN Conditions"**), 26 October 2015 ([https://www.danone.com/en/emtn-prospectus/2015/Danone\\_2015\\_Base\\_Prospectus.pdf](https://www.danone.com/en/emtn-prospectus/2015/Danone_2015_Base_Prospectus.pdf)), the **"2015 EMTN Conditions"**), 26 September 2016 ([https://www.danone.com/en/emtn-prospectus/2016/Update\\_Base\\_Prospectus.pdf](https://www.danone.com/en/emtn-prospectus/2016/Update_Base_Prospectus.pdf)), the **"2016 EMTN Conditions"**), 20 October 2017 ([https://www.danone.com/en/emtn-prospectus/2017/Danone\\_2017\\_Base\\_Prospectus.pdf](https://www.danone.com/en/emtn-prospectus/2017/Danone_2017_Base_Prospectus.pdf)), the **"2017 EMTN Conditions"**), 12 April 2019 ([https://www.danone.com/en/emtn-prospectus/2019/danone-2019\\_base-prospectus\\_visa.pdf](https://www.danone.com/en/emtn-prospectus/2019/danone-2019_base-prospectus_visa.pdf)), the **"2019 EMTN Conditions"**), 9 April 2020 ([https://www.danone.com/content/dam/danone-corp/danone-com/investors/fr-emtn-prospectus/2020/emtnprospectus/2020\\_EMTN\\_Base\\_Prospectus.pdf](https://www.danone.com/content/dam/danone-corp/danone-com/investors/fr-emtn-prospectus/2020/emtnprospectus/2020_EMTN_Base_Prospectus.pdf)), the **"2020 EMTN Conditions"**), 21 April 2021 ([https://www.danone.com/content/dam/danone-corp/danone-com/investors/en-emtn-prospectus/2021/emtnprospectus/Danone\\_2021\\_Base\\_Prospectus.pdf](https://www.danone.com/content/dam/danone-corp/danone-com/investors/en-emtn-prospectus/2021/emtnprospectus/Danone_2021_Base_Prospectus.pdf)), the **"2021 EMTN Conditions"**) and 18 May 2022 (<https://www.danone.com/content/dam/danone-corp/danone-com/investors/fr-emtn-prospectus/2022/emtnprospectus/danone2022baseprospectus.pdf>), the **"2022 EMTN Conditions"**) and, together with the 2014 EMTN Conditions, the 2015 EMTN Conditions, the 2016 EMTN Conditions, the 2017 EMTN Conditions, the 2019 EMTN Conditions, the 2020 EMTN Conditions and the 2021 EMTN Conditions, the **"EMTN Previous Conditions"**),

which shall be deemed to be incorporated by reference, save that any statement contained in a document which is incorporated by reference herein shall be deemed to be modified or superseded for the purpose of this Base Prospectus to the extent that a statement contained herein modifies or supersedes such earlier statement (whether expressly, by implication or otherwise).

For information purposes only, the English language translations of (i) the 2021 Universal Registration Document, (ii) the 2022 Universal Registration Document and (iii) the 2023 Interim Financial Report are available on the website of the Issuer ([www.danone.com](http://www.danone.com)). For ease of reference, the page numbering of the English language translations of the documents incorporated by reference is identical to the French versions. These English language translations are not incorporated by reference herein.

This Base Prospectus and copies of all documents incorporated by reference in this Base Prospectus shall be published on and may be obtained from the website of the Issuer ([www.danone.com](http://www.danone.com)).

The non-incorporated parts of the documents incorporated by reference in this Base Prospectus shall not form part of this Base Prospectus and are either not relevant for the investors or covered elsewhere in this Base Prospectus.

Other than in relation to the documents which are incorporated by reference, the information on the websites to which this Base Prospectus refers does not form part of this Base Prospectus and has not been scrutinised or approved by the AMF.

For the purpose of the Prospectus Regulation, information can be found in the documents incorporated by reference in this Base Prospectus in accordance with the following cross-reference table (in which the numbering refers to the relevant items of Annex 7 of Commission Delegated Regulation (EU) 2019/980 of 14 March 2019 supplementing the Prospectus Regulation, as amended, (the “**Commission Delegated Regulation**”)).

Any information not listed in the cross-reference list below but included in the documents incorporated by reference shall not form part of this Base Prospectus and is not relevant for investors:

<b>Commission Delegated Regulation – Annex 7</b>	<b>2023 Interim Financial Report</b>	<b>2022 Universal Registration Document</b>	<b>2021 Universal Registration Document</b>
<b>2 STATUTORY AUDITORS</b>			
2.1 Names and addresses of the issuer’s auditors for the period covered by the historical financial information (together with their membership in a professional body).		Page 6	Page 6
2.2 If auditors have resigned, been removed or not been re-appointed during the period covered by the historical financial information, details if material.		Not applicable	Not applicable
<b>3 RISK FACTORS</b>			
3.1 A description of the material risks that are specific to the issuer and that may affect the issuer’s ability to fulfil its obligations under the securities, in a limited number of categories, in a section headed ‘Risk Factors’.  In each category the most material risks, in the assessment of the issuer, offeror or person asking for admission to trading on a regulated market, taking into account the negative impact on the issuer and the probability of their occurrence, shall	Page 11	Pages 22 to 34	

<b>Commission Delegated Regulation – Annex 7</b>	<b>2023 Interim Financial Report</b>	<b>2022 Universal Registration Document</b>	<b>2021 Universal Registration Document</b>
be set out first. The risk factors shall be corroborated by the content of the registration document.			
<b>4 INFORMATION ABOUT THE ISSUER</b>			
<b>4.1 <u>History and development of the Issuer:</u></b>			
4.1.1 the legal and commercial name of the Issuer;		Page 6	
4.1.2 the place of registration of the issuer and its registration number and legal entity identifier ('LEI');		Page 6	
4.1.3 the date of incorporation and the length of life of the Issuer, except where indefinite; and		Page 6	
4.1.4 the domicile and legal form of the issuer, the legislation under which the issuer operates, its country of incorporation, the address, telephone number of its registered office (or principal place of business if different from its registered office) and website of the issuer, if any, with a disclaimer that the information on the website does not form part of the prospectus unless that information is incorporated by reference into the prospectus.		Page 6	
4.1.5 Any recent events particular to the issuer and which are to a material extent relevant to an evaluation of the issuer's solvency.	Pages 23 to 26 and 33	Pages 42 to 57 and 114-115	
<b>5 BUSINESS OVERVIEW</b>			
<b>5.1 <u>Principal activities:</u></b>			
5.1.1 A brief description of the issuer's principal activities stating the main categories of products sold and/or services performed; and		Pages 12 to 20 and 44-45	
5.1.2 The basis for any statements in the registration document made by the issuer regarding its competitive position.		Pages 7 (18 <sup>th</sup> and 19 <sup>th</sup> items in the table of paragraph 1.2), 12-13 and 19	
<b>6 ORGANISATIONAL STRUCTURE</b>			
6.1 If the issuer is part of a group, a brief description of the group and the issuer's position within the group. This may be in the form of, or accompanied by, a diagram of the organisational		Pages 21 and 43	

<b>Commission Delegated Regulation – Annex 7</b>	<b>2023 Interim Financial Report</b>	<b>2022 Universal Registration Document</b>	<b>2021 Universal Registration Document</b>
structure if this helps to clarify the structure.			
6.2 If the issuer is dependent upon other entities within the group, this must be clearly stated together with an explanation of this dependence.		Not applicable	
<b>7 TREND INFORMATION</b>			
<p>7.1 A description of:</p> <p>(a) any material adverse change in the prospects of the issuer since the date of its last published audited financial statements; and</p> <p>(b) any significant change in the financial performance of the group since the end of the last financial period for which financial information has been published to the date of the registration document.</p> <p>If neither of the above are applicable then the issuer should include (an) appropriate negative statement(s).</p>	Pages 11, 23 to 24 and 33		
<b>9 ADMINISTRATIVE, MANAGEMENT, AND SUPERVISORY BODIES</b>			
<p>9.1 Names, business addresses and functions in the issuer of the following persons, and an indication of the principal activities performed by them outside the issuer where these are significant with respect to that issuer:</p> <p>(a) members of the administrative, management or supervisory bodies;</p> <p>(b) partners with unlimited liability, in the case of a limited partnership with a share capital.</p>		Pages 232, 241-242 and 254 to 263  Not applicable	
<p>9.2 <b><u>Administrative, Management, and Supervisory bodies conflicts of interests</u></b></p> <p>Potential conflicts of interests between any duties to the issuer, of the persons referred to in item 9.1, and their private interests and or other duties must be clearly stated. In the event that there are no such conflicts, a statement to that effect must be made.</p>		Pages 238 to 240	

<b>Commission Delegated Regulation – Annex 7</b>	<b>2023 Interim Financial Report</b>	<b>2022 Universal Registration Document</b>	<b>2021 Universal Registration Document</b>
<b>10 MAJOR SHAREHOLDERS</b>			
10.1 To the extent known to the issuer, state whether the issuer is directly or indirectly owned or controlled and by whom and describe the nature of such control, and describe the measures in place to ensure that such control is not abused.		Pages 329 to 331	
10.2 A description of any arrangements, known to the issuer, the operation of which may at a subsequent date result in a change in control of the issuer.		Page 333	
<b>11 FINANCIAL INFORMATION CONCERNING THE ISSUER'S ASSETS AND LIABILITIES, FINANCIAL POSITION AND PROFITS AND LOSSES</b>			
11.1 <b><u>Historical Financial Information</u></b>			
11.1.1 Historical financial information covering the latest two financial years (at least 24 months) or such shorter period as the issuer has been in operation and the audit report in respect of each year.  (a) balance sheet; (b) income statement; (c) cash flow statement; and (d) accounting policies and explanatory notes	Pages 14 to 34  Pages 16 and 17 Pages 14 and 15 Page 18 Pages 20 to 33	Pages 62 to 121  Pages 64 and 65 Pages 62 and 63 Page 66 Pages 69 to 116	Pages 60 to 121  Pages 62 and 63 Pages 60 and 61 Page 64 Pages 67 to 115
11.1.3 <b><u>Accounting standards</u></b>	Pages 21 and 22	Pages 70 and 71	Pages 68 and 69
The financial information must be prepared according to International Financial Reporting Standards as endorsed in the Union based on Regulation (EC) No 1606/2002.  If Regulation (EC) No 1606/2002 is not applicable the financial statements must be prepared according to:  (a) a Member State's national accounting standards for issuers from the EEA as required by Directive 2013/34/EU;  (b) a third country's national accounting standards equivalent to Regulation (EC) No 1606/2002 for third country issuers.			



<b>Commission Delegated Regulation – Annex 7</b>	<b>2023 Interim Financial Report</b>	<b>2022 Universal Registration Document</b>	<b>2021 Universal Registration Document</b>
<p>Otherwise the following information must be included in the registration document:</p> <p>(a) a prominent statement that the financial information included in the registration document has not been prepared in accordance with International Financial Reporting Standards as endorsed in the Union based on Regulation (EC) No 1606/2002 and that there may be material differences in the financial information had Regulation (EC) No 1606/2002 been applied to the historical financial information;</p> <p>(b) immediately following the historical financial information a narrative description of the differences between Regulation (EC) No 1606/2002 as adopted by the Union and the accounting principles adopted by the issuer in preparing its annual financial statements.</p>			
<p>11.1.5 <b><u>Consolidated financial statements</u></b></p>	<p>Pages 14 to 34</p>	<p>Pages 62 to 121</p>	<p>Pages 60 to 121</p>
<p>If the issuer prepares both stand-alone and consolidated financial statements, include at least the consolidated financial statements in the registration document.</p>			

<b>Commission Delegated Regulation – Annex 7</b>	<b>2023 Interim Financial Report</b>	<b>2022 Universal Registration Document</b>	<b>2021 Universal Registration Document</b>
11.2 <b><u>Auditing of historical annual financial information</u></b>			
11.2.1 The historical annual financial information must be independently audited. The audit report shall be prepared in accordance with Directive 2006/43/EC and Regulation (EU) No 537/2014.	Page 34 (limited review)	Pages 117 to 121	Pages 116 to 121
11.2.1a Where audit reports on the annual financial statements have been refused by the statutory auditors or where they contain qualifications, modifications of opinion, disclaimers or an emphasis of matter, the reason must be given, and such qualifications, modifications, disclaimers or emphasis of matter must be reproduced in full.	Not applicable	Not applicable	Not applicable
11.3 <b><u>Legal and arbitration proceedings</u></b>			
11.3.1 Information on any governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which the issuer is aware), during a period covering at least the previous 12 months which may have, or have had in the recent past, significant effects on the issuer and/or group's financial position or profitability, or provide an appropriate negative statement.	Page 33	Pages 114 and 135	
11.4 <b><u>Significant change in the issuer's financial position</u></b>			
11.4.1 A description of any significant change in the financial position of the group which has occurred since the end of the last financial period for which either audited financial information or interim financial information have been published, or provide an appropriate negative statement.	Page 33	Page 57	
<b>12 MATERIAL CONTRACTS</b>			
12 A brief summary of all material contracts that are not entered into in the ordinary course of the issuer's business, which could result in any group member being under an obligation or entitlement that is material to the issuer's ability to meet its obligation to security holders in respect of the securities being issued.		Page 45	

The EMTN Previous Conditions are incorporated by reference in this Base Prospectus for the purpose only of further issues of Notes to be assimilated (*assimilées*) and form a single series with Notes already issued pursuant to the relevant EMTN Previous Conditions.

<b>EMTN Previous Conditions</b>	
Base prospectus dated 24 October 2014	Pages 27 to 62
Base prospectus dated 26 October 2015	Pages 28 to 60
Base prospectus dated 26 September 2016	Pages 26 to 57
Base prospectus dated 20 October 2017	Pages 30 to 62
Base prospectus dated 12 April 2019	Pages 36 to 79
Base prospectus dated 9 April 2020	Pages 38 to 82
Base prospectus dated 21 April 2021	Pages 41 to 85
Base prospectus dated 18 May 2022	Pages 40 to 112

"

## RECENT DEVELOPMENTS

The following statement is included in the section entitled "Recent Developments" on page 117 of the Base Prospectus:

"Sanjiv Mehta was appointed as independent director (*administrateur indépendant*) at the Issuer's general meeting on 27 April 2023. He has entered into its functions on 1<sup>st</sup> July 2023.

Information required by item 9.1 of Annex 7 of the Commission Delegated Regulation (EU) 2019/980:

- (i) Name: Sanjiv Mehta.
- (ii) Function within the Issuer: independent director (*administrateur indépendant*).
- (iii) Business address: 17, boulevard Haussmann, Paris (75009), France.
- (iv) Principal activities outside of the Issuer as at 31 December 2022:
  - non-executive president of PT Indonesia Tbk;
  - director of Air India Limited.

Information required by item 9.2 of Annex 7 of the Commission Delegated Regulation (EU) 2019/980: to the Issuer's knowledge, there are no potential conflicts of interests between any director's duties to the Issuer and their private interests and/or other duties."

\*\*\*

The following press releases and statement are included in the section entitled "Recent Developments" on page 117 of the Base Prospectus:

On 26 July 2023, the Issuer published the following press release:

### "2023 Half-Year Results

Press release – Paris, July 26, 2023

## Solid first half of the year Making consistent progress on Renew Danone

- **Net sales reached €14,167m in H1 2023**, up +6.3% on a reported basis and **+8.4% on a like-for-like (LFL) basis**, with price up +9.4%, and volume/mix down -1.1%
- **Q2 sales growth reached +6.4% on a LFL basis**, with price up +8.7% and volume/mix down -2.3%
  - +6.5% in Europe, driven by France, Poland and Spain; further progress on EDP portfolio transformation
  - +5.0% in North America, led by Yogurt, Coffee Creations and Waters
  - +9.6% in China, North Asia & Oceania, supported by all categories
  - +10.8% in Latin America, led by EDP and Specialized Nutrition
  - +3.9% in Rest of the World, with Q2 performance normalizing after Q1 one-offs
- **Recurring operating margin up +14 bps at 12.2%**; significant reinvestments in A&P, product superiority and capabilities (-99 bps impact)
- Operational performance driving earnings: **recurring EPS at €1.76**, up +7.6% from last year
- **€1.1 bn free-cash-flow**, driven by operational performance and supported by disciplined capital allocation
- **2023 guidance reiterated**: like-for-like sales growth between +4 and +6%; moderate improvement in recurring operating margin

### 2023 Half-Year Key Figures

<i>in millions of euros except if stated otherwise</i>	H1 2022	H1 2023	Reported Change	Like-for-like Change (LFL)
--	---------	---------	-----------------	----------------------------

<b>Sales</b>	<b>13,325</b>	<b>14,167</b>	<b>+6.3%</b>	<b>+8.4%</b>
<b>Recurring operating income</b>	<b>1,612</b>	<b>1,734</b>	<b>+7.6%</b>	<b>+5.8%</b>
<b>Recurring operating margin</b>	<b>12.1%</b>	<b>12.2%</b>	<b>+14 bps</b>	<b>-30 bps</b>
Non-recurring operating income and expenses	(233)	(53)	+180	
Operating income	1,380	1,681	+21.9%	
Operating margin	10.4%	11.9%	+152 bps	
<b>Recurring net income – Group share</b>	<b>1,051</b>	<b>1,133</b>	<b>+7.8%</b>	
Non-recurring net income – Group share	(314)	(40)	+273	
Net income – Group share	737	1,093	+48.2%	
<b>Recurring EPS (€)</b>	<b>1.63</b>	<b>1.76</b>	<b>+7.6%</b>	
EPS (€)	1.14	1.70	+48.3%	
<b>Free cash flow</b>	<b>674</b>	<b>1,124</b>	<b>+66.9%</b>	
Cash flow from operating activities	970	1,424	+46.8%	

## Antoine de Saint-Affrique: CEO statement

"As we navigate an unprecedented situation in Russia, my very first thoughts go to all our colleagues there.

In an environment that remains volatile and challenging, we further built our track record of delivery with a solid first half of the year: like-for-like sales growth reached +8.4%, supported by resilient volume/mix and continued pricing. Growth remains broad-based, with all geographies contributing.

These past few months, we made consistent progress on our strategic agenda, further strengthening our Core, investing behind our winners and actively addressing our underperformers. And while we see green shoots of success across the portfolio - exemplified by the continued performance of International Delight, Aptamil, evian and YoPro, or the encouraging momentum behind Mizone – we know the job is not done. We remain, more than ever, focused on building further resilience into Danone, by further stepping up our execution, but also by leveraging increasingly more our Science, Operations and Investments.

Importantly, the last 18 months' efforts on restoring the fundamentals are starting to pay: our gross margin has expanded in the first half of the year, which allows us to significantly invest behind our brands – 99bps in the first half – while improving margins moderately and delivering healthy free cash flows. In short, we are progressing towards the business model we strive for.

While a lot remains to be done, this makes us look at the future with confidence: this year, we expect to deliver a like-for-like sales growth in the upper end of our +4 and +6% guidance, underpinned by sequential volume/mix improvement in the second half, and moderate recurring operating margin improvement."

## I. SECOND QUARTER AND HALF-YEAR SALES

### Second quarter and half-year sales

**In Q2 2023**, consolidated sales stood at €7.2 bn, up +6.4% on a like-for-like basis, with a +8.7% contribution from price and a -2.3% contribution from volume/mix. On a reported basis, sales increased by +2.4%, reflecting notably a negative impact from forex (-4.3%) and scope (-0.4%), and a positive contribution of hyperinflation (+1.3%).

**In H1 2023**, consolidated sales stood at €14.2 bn, up +8.4% on a like-for-like basis, with a +9.4% contribution from price and a -1.1% contribution from volume/mix. On a reported basis, sales increased by +6.3%,

All references in this document to Like-for-like (LFL) changes, Recurring operating income and margin, Recurring net income, Recurring income tax rate, Recurring EPS, Free cash-flow and net financial debt, correspond to alternative performance measures not defined by IFRS. Their definitions, as well as their reconciliation with financial statements, are listed on pages 8 to 11.

notably penalized by a negative forex effect of -2.0%, reflecting in particular the depreciation of various Asian and Latin American currencies against the euro. Reported sales were also impacted by a positive contribution of hyperinflation of +1.3%, and a slightly negative scope effect of -0.5%.

## Sales by operating segment

€ million except %	Q2 2022	Q2 2023	Reported change	LFL Sales Growth	Volume/Mix Growth	H1 2022	H1 2023	Reported change	LFL Sales Growth	Volume/Mix Growth
<b>BY GEOGRAPHICAL ZONE</b>										
Europe	2,289	2,429	+6.1%	<b>+6.5%</b>	-5.1%	4,431	4,677	+5.5%	<b>+6.4%</b>	-4.6%
North America <sup>2</sup>	1,662	1,704	+2.5%	<b>+5.0%</b>	-2.7%	3,139	3,418	+8.9%	<b>+8.3%</b>	-1.0%
China, North Asia & Oceania <sup>2</sup>	936	954	+1.9%	<b>+9.6%</b>	+8.8%	1,671	1,778	+6.4%	<b>+12.4%</b>	+11.2%
Latin America <sup>3</sup>	704	779	+10.7	<b>+10.8%</b>	-2.0%	1,327	1,466	+10.5%	<b>+11.7%</b>	-1.1%
Rest of the World	1,476	1,369	-7.2%	<b>+3.9%</b>	-4.3%	2,756	2,828	+2.6%	<b>+7.7%</b>	-2.8%
<b>BY CATEGORY</b>										
EDP	3,684	3,731	+1.3%	<b>+6.2%</b>	-3.3%	7,062	7,503	+6.3%	<b>+7.7%</b>	-3.3%
Specialized Nutrition	2,106	2,142	+1.7%	<b>+4.9%</b>	-1.7%	4,029	4,250	+5.5%	<b>+8.3%</b>	+1.7%
Waters	1,277	1,362	+6.6%	<b>+9.6%</b>	0.0%	2,234	2,413	+8.0%	<b>+10.6%</b>	+1.1%
<b>TOTAL</b>	<b>7,067</b>	<b>7,235</b>	<b>+2.4%</b>	<b>+6.4%</b>	<b>-2.3%</b>	<b>13,325</b>	<b>14,167</b>	<b>+6.3%</b>	<b>+8.4%</b>	<b>-1.1%</b>

In the second quarter, **Europe** sales were up +6.5% on a like-for-like basis, with price up +11.7% and volume/mix down -5.1%. Growth was led by France, Poland and Spain, while Germany progressively recovers after several months of supply disruptions and temporary delistings. By category, Specialized Nutrition and Waters registered resilient growth, while EDP made further progress in its portfolio transformation. In **North America**, sales were up +5.0% on a like-for-like basis, with price up +7.7% and volume/mix down -2.7%. Growth was led by Yogurt, Coffee Creations and Waters, with Oikos, *International Delight*, *Stok* and *evian* growing at a double-digit rate, while Plant-based is lapping a high base of comparison. Specialized Nutrition also lapped the high base of last year driven by the shipments realized in the context of *Operation Fly Formula*. **China, North Asia & Oceania** posted sales growth of +9.6% on a like-for-like basis, led by +0.8% growth in price and +8.8% growth in volume/mix. In China, *Aptamil* continued to deliver solid growth in Infant Nutrition, coupled with further market share gains, while *Nutrison* and *Neocate* posted strong growth in Adult Nutrition and Pediatric Specialties respectively. In Waters, *Mizone* registered mid-teens growth, driven by volumes, with market share gains, while in EDP, Japan delivered another quarter of double-digit growth. **Latin America** posted sales growth of +10.8% on a like-for-like basis, with a +12.9% increase in price and a -2.0% decline in volume/mix, led by *Danonino* and *Danette* in Mexico and by *Danone* and *Yopro* in Brazil. In the **Rest of the World**, the performance normalized in the second quarter, after favorable calendar effects in Q1. Sales were up +3.9% on a like-for-like basis, with price up +8.2% and volume/mix down -4.3%, led by key Specialized Nutrition platforms.

<sup>1</sup>United States and Canada; <sup>2</sup>China, Japan, Australia and New Zealand; <sup>3</sup>Mexico, Brazil, Argentina and Uruguay

## Recurring Operating Margin

Recurring operating profit (€m) and margin (%)	H1 2022		H1 2023		Change	
	€m	Margin (%)	€m	Margin (%)	Reported	Like-for-like
<b>BY GEOGRAPHICAL ZONE</b>						
Europe	574	12.9%	497	10.6%	-232 bps	-290 bps
North America <sup>3</sup>	254	8.1%	353	10.3%	+222 bps	+229 bps
China, North Asia & Oceania <sup>2</sup>	534	32.0%	549	30.9%	-107 bps	-156 bps
Latin America <sup>3</sup>	-1	-0.1%	42	2.8%	+291 bps	+155 bps
Rest of the World	251	9.1%	294	10.4%	+127 bps	+13 bps
<b>BY CATEGORY</b>						
EDP	494	7.0%	605	8.1%	+107 bps	+102 bps
Specialized Nutrition	933	23.2%	885	20.8%	-235 bps	-351 bps
Waters	185	8.3%	244	10.1%	+185 bps	+116 bps
<b>Total</b>	<b>1,612</b>	<b>12.1%</b>	<b>1,734</b>	<b>12.2%</b>	<b>+14 bps</b>	<b>-30 bps</b>

Danone's **recurring operating income** reached €1.7 bn in H1 2023. **Recurring operating margin** stood at 12.2%, up +14 basis points (bps) compared to last year. This increase was mainly driven by the improvement of topline drivers – including volume, mix and price – for a combined estimated impact of c. +630 bps. This positive effect was partially offset by the still strong negative impact of input-cost inflation net of productivity, at c. -540 bps.

Besides, Danone continued to step-up its reinvestments in A&P, product superiority and capabilities, that had a negative effect of -99 bps in H1 2023. Finally, Overheads before reinvestments had a positive effect of +7 bps.

In addition to operating effects, reported margin also includes the positive impact of Forex and others, changes in scope, and contribution from hyperinflation, as well as the negative effects from other income and expenses, for a total combined effect of +13 bps.

## Net income and Earnings per share

in millions of euros except if stated otherwise	H1 2022			H1 2023		
	Recurring	Non-recurring	Total	Recurring	Non-recurring	Total
<b>Recurring operating income</b>	<b>1,612</b>		<b>1,612</b>	<b>1,734</b>		<b>1,734</b>
Other operating income and expense		(233)	(233)		(53)	(53)
<b>Operating income</b>	<b>1,612</b>	<b>(233)</b>	<b>1,380</b>	<b>1,734</b>	<b>(53)</b>	<b>1,681</b>

<sup>1</sup>United States and Canada; <sup>2</sup>China, Japan, Australia and New Zealand; <sup>3</sup>Mexico, Brazil, Argentina and Uruguay

Cost of net debt	(78)		(78)	(74)		(74)
Other financial income and expense	(69)	6	(63)	(67)	(15)	(83)
<b>Income before taxes</b>	<b>1,466</b>	<b>(227)</b>	<b>1,239</b>	<b>1,593</b>	<b>(68)</b>	<b>1,525</b>
Income tax	(403)	28	(376)	(435)	6	(429)
Effective tax rate	27.5%		30.3%	27.3%		28.1%
<b>Net income from fully consolidated companies</b>	<b>1,063</b>	<b>(199)</b>	<b>863</b>	<b>1,158</b>	<b>(62)</b>	<b>1,095</b>
Share of profit (loss) of equity-accounted companies	25	(114)	(89)	14	19	33
<b>Net income</b>	<b>1,088</b>	<b>(313)</b>	<b>774</b>	<b>1,172</b>	<b>(44)</b>	<b>1,129</b>
• <b>Group share</b>	<b>1,051</b>	<b>(314)</b>	<b>737</b>	<b>1,133</b>	<b>(40)</b>	<b>1,093</b>
• Non-controlling interests	37	0	37	39	(3)	36
<b>EPS (€)</b>	<b>1.63</b>		<b>1.14</b>	<b>1.76</b>		<b>1.70</b>

**Other operating income and expense** reached -€53 million in H1 2023, vs -€233 million in the prior year. Reported operating margin was up +152 bps, from 10.4% to 11.9%.

**Share of profit of equity-accounted companies** stood at €33 million, mainly reflecting the gain on disposal of the 25% stake in Yashili in H1 2023, improving from -€89 million last year, which reflected the impairment related to the disposal of the remaining minority investments in Mengniu partnerships.

As a result, **Reported EPS** increased by +48.3% to €1.70, while **Recurring EPS** was up +7.6% to €1.76.

## Cash flow and Debt

**Free cash flow** reached €1,124 million in H1 2023, increasing from €674 million in H1 2022, reflecting the significant increase in cash-flow from operating activities. Capex stood at €310 million.

As of June 30, 2023, Danone's **net debt stood** at €11.2 bn.

## Sales by geography and category

Q2 2023	Europe		North America		China/North Asia/Oceania		AMEA, CIS & Latin America		Total	
	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)
EDP	1,085	+5.8%	1,539	+5.2%	96	+14.9%	1,012	+7.6%	3,731	+6.2%
Specialized Nutrition	766	+3.4%	87	-9.0%	611	+6.9%	677	+7.0%	2,142	+4.9%
Waters	577	+12.4%	78	+22.3%	247	+15.1%	459	+2.0%	1,362	+9.6%
<b>Total Company</b>	<b>2,429</b>	<b>+6.5%</b>	<b>1,704</b>	<b>+5.0%</b>	<b>954</b>	<b>+9.6%</b>	<b>2,149</b>	<b>+6.1%</b>	<b>7,235</b>	<b>+6.4%</b>

H1 2023	Europe		North America		China/North Asia/Oceania		AMEA, CIS & Latin America		Total	
	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)
EDP	2,152	+5.5%	3,106	+8.4%	180	+16.9%	2,065	+8.1%	7,503	+7.7%
Specialized Nutrition	1,518	+3.0%	173	-1.9%	1,220	+10.8%	1,340	+14.1%	4,250	+8.3%



Waters	1,007	+14.0%	139	+21.0%	378	+15.9%	889	+3.9%	2,413	+10.6%
<b>Total Company</b>	<b>4,677</b>	<b>+6.4%</b>	<b>3,418</b>	<b>+8.3%</b>	<b>1,778</b>	<b>+12.4%</b>	<b>4,294</b>	<b>+9.0%</b>	<b>14,167</b>	<b>+8.4%</b>

## II. EDP RUSSIA UPDATE

On October 14, 2022, Danone launched a process to transfer the control of its EDP (Essential Dairy & Plant-based) Business in Russia, which was progressing according to the expected schedule.

On July 16, 2023, Danone has taken note of the decision of the Russian authorities aiming at placing Danone Russia (EDP) under the temporary external administration of the Russian Federal Agency for State Property Management (Rosimushchestvo).

On July 18, 2023, the Russian authorities indicated that the Board of Directors and CEO of Danone Russia (EDP) had been changed. These changes took place without the knowledge of, or approval by, Danone. While Danone no longer retains control of the management of its EDP operations in Russia, it remains their legal owner.

As a result, and as per applicable accounting standards (IFRS), Danone will deconsolidate its EDP Russia operations in July 2023, triggering an approximately €(0.2)bn cash impairment. In addition, Danone recognizes a non-cash RUB / EUR FX translation difference of approximately €(0.5)bn, which has no impact on Group's total equity. Both will be recognized on December 31, 2023.

EDP Russia will therefore be taken out of Danone's like for like perimeter as of July 2023; Danone's H2 2023 recurring performance will be reported excluding the contribution of EDP Russia.

Danone will continue to investigate the situation to understand the implications of the decisions of the Russian authorities on the ongoing EDP operations of Danone in Russia, as well as on the ongoing sale process. Danone will continue to provide information on material developments related to the situation of its EDP operations in Russia and keeps investigating how to protect its assets and its rights as shareholder, with a first priority to ensure people safety.

## III. 2023 GUIDANCE

Like-for-like sales growth expected between +4 and +6%, with moderate recurring operating margin improvement.

## IV. MAJOR DEVELOPMENTS OVER THE PERIOD

- **April 27, 2023:** At Danone's 2023 Annual General Meeting, shareholders approved all resolutions submitted to its approval by the Board of Directors, including the distribution of a dividend of €2.00 per share in cash, the appointment of Sanjiv Mehta as Director, the renewals of terms of office of Valérie Chapoulaud-Floquet and Gilles Schnepf, and the ratification of the co-opting of Gilbert Ghostine and Lise Kingo, as Directors.
- **May 15, 2023:** Danone issued a €800 million bond with an 8-year maturity and a 3.47% coupon. The settlement took place on May 22, 2023, and the bonds are listed on Euronext Paris.

## V. NEW FINANCIAL DISCLOSURE PRO FORMA

### Financial disclosure

Danone's external reporting has been adjusted to reflect the organizational changes. Starting from Q1 2023, the company reports its key indicators (net sales, like-for-like sales growth, recurring operating income and recurring operating margin) along five adjusted operating segments:

- Europe, which includes Ukraine (was previously part of Rest of the World zone);
- North America, which includes the United States and Canada (unchanged);
- China, North Asia, Oceania (unchanged);
- Latin America (was previously part of Rest of the World zone);
- Rest of the World, which includes AMEA (Asia, Middle East including Turkey, Africa) and CIS.

The global category reporting remains unchanged, and Danone continues to report performance, on both net sales and recurring operating income and margin, for EDP, Specialized Nutrition and Waters.

### Like-For-Like definition

All countries with hyperinflationary economies are now included in our like-for-like changes. However, in order to limit the distorting effect of hyperinflation, net sales growth in excess of around 26% per year are excluded from like-for-like net sales growth calculation in hyperinflationary economies. Indeed, a three-year average at 26% would generally trigger hyperinflation as defined by IFRS rules.

### H1 and FY 2022 sales restated by new operating segments and new LFL methodology

H1 2022	Europe		North America		China/North Asia/Oceania		AMEA, CIS & Latin America		Total	
	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)
EDP	2,087	-0.2%	2,851	+6.4%	166	+9.6%	1,958	+7.9%	7,062	+4.7%
Specialized Nutrition	1,485	+8.4%	174	+14.0%	1,160	+15.0%	1,209	+6.1%	4,029	+9.7%
Waters	859	+11.4%	114	+18.3%	345	-9.9%	916	+14.2%	2,234	+8.8%
<b>Total Company</b>	<b>4,431</b>	<b>+4.7%</b>	<b>3,139</b>	<b>+7.2%</b>	<b>1,671</b>	<b>+8.3%</b>	<b>4,083</b>	<b>+8.6%</b>	<b>13,325</b>	<b>+6.9%</b>

FY 2022	Europe		North America		China/North Asia/Oceania		AMEA, CIS & Latin America		Total	
	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)	Net sales (€m)	LFL sales growth (%)
EDP	4,137	+0.6%	6,085	+8.1%	340	+12.4%	4,237	+8.0%	14,799	+5.8%
Specialized Nutrition	2,977	+8.3%	376	+15.6%	2,431	+9.3%	2,535	+9.7%	8,319	+9.3%
Waters	1,757	+8.5%	251	+19.0%	656	-4.4%	1,879	+10.2%	4,543	+7.5%
<b>Total Company</b>	<b>8,871</b>	<b>+4.6%</b>	<b>6,712</b>	<b>+8.9%</b>	<b>3,428</b>	<b>+6.7%</b>	<b>8,651</b>	<b>+9.0%</b>	<b>27,661</b>	<b>+7.1%</b>

### H1 and FY 2022 margin restated by new operating segments

Recurring operating profit (€m) and margin (%)	H1 2022		FY 2022	
	€m	Margin (%)	€m	Margin (%)

#### **BY GEOGRAPHICAL ZONE**

Europe	574	12.9%	1,084	12.2%
North America <sup>4</sup>	254	8.1%	679	10.1%
China, North Asia & Oceania <sup>2</sup>	534	32.0%	1,037	30.2%
Latin America <sup>3</sup>	-1	-0.1%	55	1.9%
Rest of the World	251	9.1%	522	8.9%

#### **BY CATEGORY**

<sup>1</sup>United States and Canada; <sup>2</sup>China, Japan, Australia and New Zealand

EDP	494	7.0%	1,207	8.2%
Specialized Nutrition	933	23.2%	1,799	21.6%
Waters	185	8.3%	370	8.2%

<b>Total</b>	<b>1,612</b>	<b>12.1%</b>	<b>3,377</b>	<b>12.2%</b>
--------------	--------------	--------------	--------------	--------------

## VI. ALTERNATIVE PERFORMANCE MEASURES NOT DEFINED BY IFRS

### IAS 29: impact on reported data

All necessary conditions have been reached (including 3-year cumulative rate of inflation for consumer prices exceeding the 100% threshold reached during the first half 2022) to now consider Turkey as "hyperinflationary" as defined by IFRS rules and therefore that IAS 29 rule related to Financial Reporting in Hyperinflationary Economies becomes applicable to the country. Consequently, Danone applies IAS 29 in Turkey with an effective date of January 1st, 2022.

Adoption of IAS 29 in hyperinflationary countries requires its non-monetary assets and liabilities and its income statement to be restated to reflect the changes in the general pricing power of its functional currency, leading to a gain or loss on the net monetary position included in the net income. Moreover, its financial statements are converted into euros using the closing exchange rate of the relevant period.

IAS 29: impact on reported data € million except %	Q2 2023	H1 2023
Sales	-17.7	-54.2
Sales growth (%)	-0.24%	-0.38%
Recurring Operating Income		-35
Recurring Net Income – Group share		-72

### Breakdown by quarter of H1 2023 sales after application of IAS 29

H1 2023 sales correspond to the addition of:

- Q2 2023 reported sales;
- Q1 2023 sales resulting from the application of IAS 29 until June 30, 2023, to sales of entities in hyperinflation countries (application of the inflation rate until June 30, 2023, and translation into euros using the June 30, 2023, closing rate) and provided in the table below for information (unaudited data).

€ million	Q1 2023 <sup>1</sup>	Q2 2023	H1 2023
Europe	2,248	2,429	4,677
North America	1,714	1,704	3,418
China, North Asia & Oceania	824	954	1,778
Latin America	687	779	1,466
Rest of the World	1,459	1,369	2,828
<b>Total</b>	<b>6,932</b>	<b>7,235</b>	<b>14,167</b>

<sup>1</sup>Results from the application of IAS 29 until June 30, 2023, to Q1 sales of entities of hyperinflation countries.

### Financial indicators not defined in IFRS

Due to rounding, the sum of values presented may differ from totals as reported. Such differences are not material.

**Like-for-like changes** in sales, recurring operating income and recurring operating margin reflect Danone's organic performance and essentially exclude the impact of:

- changes in consolidation scope, with indicators related to a given fiscal year calculated on the basis of previous-year scope, both previous-year and current-year scopes excluding entities in countries under hyperinflation according to IAS 29 during the previous year (as for Argentinian entities since January 1, 2019, and except for Turkey);
- changes in applicable accounting principles;
- changes in exchange rates with both previous-year and current-year indicators calculated using the same exchange rates (the exchange rate used is a projected annual rate determined by Danone for the current year and applied to both previous and current years).

**Bridge from reported data to like-for-like data**

(€ million except %)	H1 2022	Like-for-like change	Impact of changes in scope of consolidation	Impact of changes in exchange rates & others incl. IAS 29	Organic contribution from hyperinflation countries	Reported change	H1 2023
<b>Sales</b>	<b>13,325</b>	+8.4%	-0.5%	-2.9%	+1.3%	<b>+6.3%</b>	<b>14,167</b>
<b>Recurring operating margin</b>	<b>12.1%</b>	-30 bps	+6 bps	+39 bps	-2 bps	<b>+14 bps</b>	<b>12.2%</b>

**Recurring operating income** is defined as Danone's operating income excluding Other operating income and expenses. Other operating income and expenses comprise items that, because of their significant or unusual nature, cannot be viewed as inherent to Danone's recurring activity and have limited predictive value, thus distorting the assessment of its recurring operating performance and its evolution. These mainly include:

- capital gains and losses on disposals of fully consolidated companies;
- impairment charges on intangible assets with indefinite useful lives;
- costs related to strategic restructurings or transformation plans;
- costs related to major external growth transactions;
- costs related to major crisis and major litigations;
- in connection with IFRS 3 (Revised) and IAS 27 (Revised) relating to business combinations, (i) acquisition costs related to business combinations, (ii) revaluation profit or loss accounted for following a loss of control, and (iii) changes in earn-outs relating to business combinations and subsequent to acquisition date.

**Recurring operating margin** is defined as Recurring operating income over Sales ratio.

**Other non-recurring financial income and expense** corresponds to financial income and expense items that, in view of their significant or unusual nature, cannot be considered as inherent to Danone's recurring financial management. These mainly include changes in value of non-consolidated interests.

**Non-recurring income tax** corresponds to income tax on non-recurring items as well as tax income and expense items that, in view of their significant or unusual nature, cannot be considered as inherent to Danone's recurring performance.

**Recurring effective tax rate** measures the effective tax rate of Danone's recurring performance and is computed as the ratio of income tax related to recurring items over recurring net income before tax.

**Non-recurring share of profit of equity-accounted companies** includes items that, because of their significant or unusual nature, cannot be viewed as inherent to the companies' recurring activity and thereby distort the assessment of their recurring performance and trends in that performance. These items mainly relate to (i) capital gains and losses on disposals of investments in equity-accounted companies, (ii) impairment of goodwill, and (iii) non-recurring items, as defined by Danone, included in the share of profit of equity-accounted companies.

**Recurring net income** (or Recurring net income – Group Share) corresponds to the Group share of the consolidated Recurring net income. The Recurring net income excludes items that, because of their significant or unusual nature, cannot be viewed as inherent to Danone's recurring activity and have limited predictive value, thus distorting the assessment of its recurring performance and its evolution. Such non-recurring income and expenses correspond to Other operating income and expenses, Other non-recurring financial income and expenses, Non-recurring income tax, and Non-recurring income from equity-accounted companies. Such income and expenses, excluded from Net income, represent Non-recurring net income.

**Recurring EPS** (or Recurring net income – Group Share, per share after dilution) is defined as the ratio of Recurring net income adjusted for hybrid financing over Diluted number of shares. In compliance with IFRS, income used to calculate EPS is adjusted for the coupon related to the hybrid financing accrued for the period and presented net of tax.

	H1 2022		H1 2023	
	Recurring	Total	Recurring	Total
<b>Net income-Group share</b> (€ million)	1,051	737	1,133	1,093
Coupon related to hybrid financing net of tax (€ million)	(7)	(7)	(6)	(6)
<b>Number of shares</b>				
• Before dilution	638,514,26	638,514,26	640,196,78	640,196,78
	8	8	6	6
• After dilution	638,827,26	638,827,26	640,804,80	640,804,80
	8	8	5	5
<b>EPS</b> (€)				
• Before dilution	1.64	1.14	1.76	1.70
• After dilution	1.63	1.14	1.76	1.70

**Free cash flow** represents cash flows provided or used by operating activities less capital expenditure net of disposals and, in connection with IFRS 3 (Revised), relating to business combinations, excluding (i) acquisition costs related to business combinations, and (ii) earn-outs related to business combinations and paid subsequently to acquisition date.

(€ million)	H1 2022	H1 2023
<b>Cash-flow from operating activities</b>	<b>970</b>	<b>1,424</b>
Capital expenditure	(318)	(310)
Disposal of tangible assets & transaction fees related to business combinations <sup>1</sup>	22	10
<b>Free cash-flow</b>	<b>674</b>	<b>1,124</b>

<sup>1</sup> Represents acquisition costs related to business combinations paid during the period.

**Net financial debt** represents the net debt portion bearing interest. It corresponds to current and non-current financial debt (i) excluding Liabilities related to put options granted to non-controlling interests and earn-outs on acquisitions resulting in control and (ii) net of Cash and cash equivalents, Short term investments and Derivatives – assets managing net debt.

(€ million)	December 31, 2022	June 30, 2023
Non-current financial debt	11,238	11,162
Current financial debt	3,298	4,402
Short-term investments	(3,631)	(3,377)
Cash	(1,051)	(1,880)
Bank Overdraft	330	940
Derivatives — non-current assets <sup>1</sup>	(18)	(8)
Derivatives — current-assets <sup>1</sup>	(60)	(59)
<b>Net debt</b>	<b>10,107</b>	<b>11,180</b>

<ul style="list-style-type: none"> <li>• Liabilities related to put options granted to non-controlling interests — non-current</li> <li>• Liabilities related to put options granted to non-controlling interests and earn-outs on acquisitions resulting in control — current</li> </ul>	(59)	(0)
	(263)	(284)
<b>Net financial debt</b>	<b>9,785</b>	<b>10,896</b>

<sup>1</sup> Managing net debt only

o o O o o

#### FORWARD-LOOKING STATEMENTS

*This press release contains certain forward-looking statements concerning Danone. In some cases, you can identify these forward-looking statements by forward-looking words, such as “estimate”, “expect”, “anticipate”, “project”, “plan”, “intend”, “objective”, “believe”, “forecast”, “guidance”, “foresee”, “likely”, “may”, “should”, “goal”, “target”, “might”, “will”, “could”, “predict”, “continue”, “convinced” and “confident,” the negative or plural of these words and other comparable terminology. Forward looking statements in this document include, but are not limited to, predictions of future activities, operations, direction, performance and results of Danone.*

*Although Danone believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties, please refer to the “Risk Factor” section of Danone’s Universal Registration Document (the current version of which is available at [www.danone.com](http://www.danone.com)).*

*Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy Danone securities.*

**The presentation to analysts and investors will be broadcast live today from 8:30 a.m. (Paris time) on Danone’s website ([www.danone.com](http://www.danone.com)).**  
**Related slides will also be available on the website in the Investors section.**

## APPENDIX – Sales by geographical zone and by category (in € million)

	First quarter		Second quarter		First Half	
	2022	2023	2022	2023	2022	2023
<b>BY GEOGRAPHICAL ZONE</b>						
Europe	2,142	2,248	2,289	2,429	4,431	4,677
North America <sup>5</sup>	1,477	1,714	1,662	1,704	3,139	3,418
China, North Asia & Oceania <sup>2</sup>	735	824	936	954	1,671	1,778
Latin America <sup>3</sup>	602	689	704	779	1,327	1,466
Rest of the World	1,280	1,486	1,476	1,369	2,756	2,828
<b>BY CATEGORY</b>						
EDP	3,365	3,768	3,684	3,731	7,062	7,503
Specialized Nutrition	1,919	2,143	2,106	2,142	4,029	4,250
Waters	951	1,051	1,277	1,362	2,234	2,413
<b>TOTAL</b>	<b>6,236</b>	<b>6,962</b>	<b>7,067</b>	<b>7,235</b>	<b>13,325</b>	<b>14,167</b>

	First quarter 2023		Second quarter 2023		First Half 2023	
	Reported change	Like-for-like change	Reported change	Like-for-like change	Reported change	Like-for-like change
<b>BY GEOGRAPHICAL ZONE</b>						
Europe	+4.9%	+6.2%	+6.1%	+6.5%	+5.5%	+6.4%
North America <sup>1</sup>	+16.0%	+11.8%	+2.5%	+5.0%	+8.9%	+8.3%
China, North Asia & Oceania <sup>2</sup>	+12.1%	+16.0%	+1.9%	+9.6%	+6.4%	+12.4%
Latin America <sup>3</sup>	+14.6%	+12.6%	+10.7%	+10.8%	+10.5%	+11.7%
Rest of the World	+16.2%	+11.8%	-7.2%	+3.9%	+2.6%	+7.7%
<b>BY CATEGORY</b>						
EDP	+12.0%	+9.3%	+1.3%	+6.2%	+6.3%	+7.7%
Specialized Nutrition	+11.6%	+12.0%	+1.7%	+4.9%	+5.5%	+8.3%
Waters	+10.5%	+12.0%	+6.6%	+9.6%	+8.0%	+10.6%
<b>TOTAL</b>	<b>+11.6%</b>	<b>+10.5%</b>	<b>+2.4%</b>	<b>+6.4%</b>	<b>+6.3%</b>	<b>+8.4%</b>

"

<sup>1</sup>United States and Canada; <sup>2</sup>China, Japan, Australia and New Zealand; <sup>3</sup>Mexico, Brazil, Argentina and Uruguay

## GENERAL INFORMATION

Paragraphs (5) and (6) on page 149 of the Base Prospectus are hereby deleted in their entirety and replaced by the following:

- "(5) Save as disclosed in this Base Prospectus, there has been no significant change in the financial position or financial performance of Danone or the Group since 30 June 2023.
- (6) Save as disclosed in this Base Prospectus, there has been no material adverse change in the prospects of Danone or of the Group since 31 December 2022."

Paragraph (11) on page 150 of the Base Prospectus is hereby deleted in its entirety and replaced by the following:

- "(11) In accordance with the Prospectus Regulation, the following documents will be available, on the websites of the Issuer ([www.danone.com](http://www.danone.com)) and of the AMF ([www.amf-france.org](http://www.amf-france.org)):
- (i) the Final Terms for Notes that are listed and admitted to trading on Euronext Paris and/or in any Member State of the EEA;
  - (ii) the Base Prospectus; and
  - (iii) the documents incorporated by reference in this Base Prospectus (except with respect to the 2023 Interim Financial Report which will only be available on the website of the Issuer ([www.danone.com](http://www.danone.com)))."

Paragraph (15) on page 151 of the Base Prospectus is hereby deleted in its entirety and replaced by the following:

- "(15) PricewaterhouseCoopers Audit and Ernst & Young Audit have audited and rendered an unqualified audit report on the consolidated financial statements of Danone for the year ended 31 December 2021 prepared in accordance with IFRS as adopted by the European Union.

Mazars & Associés and Ernst & Young Audit have audited and rendered an unqualified audit report on the consolidated financial statements of Danone for the year ended 31 December 2022 prepared in accordance with IFRS as adopted by the European Union.

Mazars & Associés and Ernst & Young Audit have reviewed and rendered a report on the consolidated financial statements of Danone for the six months period ended 30 June 2023, prepared in accordance with IFRS as adopted by the European Union.

Mazars & Associés has been appointed as statutory auditors of the Issuer by the shareholders' meeting (*assemblée générale des actionnaires*) of Danone held on 26 April 2022.

PricewaterhouseCoopers Audit, Ernst & Young Audit and Mazars & Associés are regulated by the *Haut Conseil du Commissariat aux Comptes*, duly authorised as *Commissaires aux comptes* and members of the *Compagnie Régionale des Commissaires aux Comptes de Versailles et du Centre*."



## PERSON RESPONSIBLE FOR THIS FIRST PROSPECTUS SUPPLEMENT

### *In the name of the Issuer*

*We declare that to the best of our knowledge, the information contained in this First Prospectus Supplement is in accordance with the facts and this First Prospectus Supplement makes no omission likely to affect its import.*

*31 July 2023.*

Danone  
17, Boulevard Haussmann  
75009 Paris  
France

Duly represented by:  
Florence SALIBA  
*Vice-President Treasury & Financing*  
Authorised Signatory  
pursuant to a Board resolution dated 21 February 2023



### *Autorité des marchés financiers*

This First Prospectus Supplement has been approved on 31 July 2023 by the AMF, in its capacity as competent authority under Regulation (EU) 2017/1129.

The AMF has approved this First Prospectus Supplement after having verified that the information it contains is complete, coherent and comprehensible within the meaning of Regulation (EU) 2017/1129.

This approval is not a favourable opinion on the Issuer.

This First Prospectus Supplement has received approval number 23-337.